SelectScience
Join Free
Accelerating Science
NewsClinical Diagnostics

QIAGEN and Bayer HealthCare Developing Companion Diagnostics for Targeted Cancer Therapies

QIAGEN
25 Oct 2012

Product news

QIAGEN and Bayer HealthCare have announced a collaboration agreement for the development and commercialization of companion diagnostics paired with novel Bayer HealthCare drugs, initially to enhance the treatment of various solid tumors.

Companion diagnostics are tests that unlock molecular information from each patient’s tumor genome to guide treatment decisions with medications for cancers or other diseases. The parties will also collaborate on the development of novel technologies for patient profiling which may result in innovative research-use-only products for exploratory and translational medicine.

The targeted companion diagnostics will be designed to run on the QIAsymphony family of automated instruments from QIAGEN, which is transforming laboratory workflows and helping disseminate standardized, regulator-approved diagnostics.

“We are very pleased to partner with Bayer HealthCare in developing companion diagnostics to improve life for cancer patients. As healthcare providers increasingly select the right drugs based on each individual’s genomic information, the treatment of cancer is undergoing a revolution,” said Dr. Helge Lubenow, Senior Vice President Molecular Diagnostics Business Area and Member of the Executive Committee of QIAGEN. “The first collaborations for Bayer HealthCare and QIAGEN include companion diagnostics based on the identification of patients who may respond to therapies in clinically unmet disease classifications. Our agreement also lays the groundwork for a strong partnership in creating future companion diagnostics both inside and outside of oncology.”

“Partnering with QIAGEN on companion diagnostics will help Bayer HealthCare to develop innovative therapies, enabling physicians to analyze DNA and proteins from each patient. This helps to design more efficient clinical trials and to increase the overall probability of therapeutic success for patients suffering from cancer,” said Prof. Dr. Andreas Busch, Head of Global Drug Discovery and Member of the Executive Committee of Bayer HealthCare.

Links

QIAGENCompany website

Tags

Gas ChromatographyGas chromatography (GC) is an analytical technique used to separate and quantitate mixtures of small and volatile compounds. Gas chromatographs or GC systems include components such as GC columns, detectors, pumps and autosamplers. Choose from packed or capillary GC columns, flame ionization (FID), photoionization (PID) electron capture detectors and selective or non-selective detectors. Find the best gas chromatographs in our peer-reviewed product directory: compare products, check customer reviews and receive pricing direct from manufacturers.Clinical GeneticsMolecular Genetics covers the analysis of hereditary genetic disease and chromosomal abnormalities. Genetics can be analysed using DNA, RNA, and protein microarrays, PCR, RT PCR and DNA sequencing. Genetic equipment includes genetic workstations, thermal cyclers, cooling blocks and electrophoresis products. Diagnostic kits are used for DNA / RNA extraction and purification.Cancer ResearchAlthough cancer is often referred to as a single condition, it actually consists of more than 100 different diseases. Microscopy, mass spectrometry, high throughput sequencing and flow cytometry are some of the most common techniques employed in cancer research labs.Cancer DiagnosticsThere are a wide variety of diagnostic tests for cancer available, and this range continues to expand as our knowledge of cancer improves. Current diagnostic methods include biopsy, imaging and blood tests for known biomarkers. New methods in research development include liquid biopsies and cancer breathalyzers.Companion DiagnosticsCompanion diagnostics are tests, often <i>in vitro</i>, that are used to determine whether a therapeutic product will be safe and effective for use on an individual. They also identify which patients will benefit most from them. Companion diagnostic tests are often developed in conjunction with the pharmaceutical industry.

Related articles

QIAGEN and Bayer HealthCare Developing Companion Diagnostics for Targeted Cancer Therapies